MedTrace Logo

A Study to Evaluate the Efficacy and Safety of Meptin® Swinghaler and Berotec N® Metered Aerosol in Mild to Moderate Stable Asthma Patients

NCT01095016 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2013-01-16

No results posted yet for this study

Summary

This is an open-label, randomized, cross-over, active-controlled study to evaluate the efficacy and safety effects using Meptin® Swinghaler and Berotec N® Metered Aerosol in stable asthma patients

Conditions

Interventions

DRUG

Meptin swinghaler

* Dose: 10ug/puff, 2 puffs daily * Frequency: QD (total 20ug/day) * Treatment duration: 2 days

DRUG

Berotec

* Dose: 100ug/puff, 2 puffs daily * Frequency: QD (total 200ug/day) * Treatment duration: 2 days

Sponsors & Collaborators

  • Taiwan Otsuka Pharm. Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Yu-Hsiu Chung, MD · Chang Cung Memorial Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2012-09-30
Completion
2012-10-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01095016 on ClinicalTrials.gov